Structure Therapeutics

Oral small-molecule GPCR-targeted therapeutics

GPCR · Nasdaq · United States

Share price · GPCR

$17.36-36.17 (-67.57%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.1M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GPCR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 29 Sep 2026-6.8%
  2. 16 Sep 2026-8.9%
  3. 8 Sep 2026-14.7%
  4. 9 Jun 2026+9.2%
  5. 17 Apr 2026-5.1%
  6. 8 Dec 2025+102.5%
  7. 18 Nov 2025-7.9%

Share of unusual movement by asset

For each asset, the share of GPCR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
aleniglipron
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—57%
Other company news (earnings, financing, releases naming no asset)—4%
Sessions with no dated event—39%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
GLP-1 receptorSmall molecule
ObesityType 2 Diabetes

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
September 2028 (2)
aleniglipronPhase 3Obesity, Overweight, Chronic Weight Management
Est. primary completion 2028-09 · NCT07654361 · CT.gov ↗
What to watch
aleniglipronPhase 3Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
Est. primary completion 2028-09 · NCT07654374 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 December 2025Topline resultaleniglipronPhase 2b ACCESS of aleniglipron met its primary endpoint at all three doses
Structure Therapeutics · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$135M$222M+ $1.0B short-term inv.$145M-$102M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$100M$273M+ $1.1B short-term inv.$106M-$120M operating cash flowreport ↗
2026-Q1—$67M$316M+ $1.1B short-term inv.$76M$15M operating cash flowreport ↗
2025-Q3—$59M$103M+ $696M short-term inv.$66M-$51M operating cash flowreport ↗
2025-Q2—$55M$147M+ $639M short-term inv.$62M-$55M operating cash flowreport ↗
2025-Q1—$43M$152M+ $685M short-term inv.$47M-$52M operating cash flowreport ↗
2024-Q3—$33M$172M+ $743M short-term inv.$34M-$20M operating cash flowreport ↗
2024-Q2—$22M$382M+ $545M short-term inv.$26M-$26M operating cash flowreport ↗
2024-Q1—$21M$98M+ $339M short-term inv.$26M-$34M operating cash flowreport ↗
2023-Q3—$18M$51M+ $155M short-term inv.$24M-$21M operating cash flowreport ↗
2023-Q2—$19M$41M+ $184M short-term inv.$23M-$17M operating cash flowreport ↗
2023-Q1—$13M$126M+ $114M short-term inv.$18M-$20M operating cash flowreport ↗
2022-Q3—$9.2M$28M$12M-$10M operating cash flowreport ↗
2022-Q2—$10M$55M$14M-$10M operating cash flowreport ↗
2022-Q1—$8.5M$51M$13M-$14M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$225M$800M+ $647M short-term inv.$35M-$222M operating cash flowreport ↗

For full-year 2025, Structure Therapeutics did not disclose revenue. R&D expense was $225.26M, up 107.0% YoY from $108.81M. Cash and cash equivalents were $799.62M, while cash, cash equivalents and short-term investments totaled $1.4B at year-end. The company reported a full-year net loss of $141.2M, compared with $122.5M in 2024, and fourth-quarter net income of $33.0M.

The company expects its current cash to fund operations through the end of 2028. Positive aleniglipron Phase 2 ACCESS data showed up to 15.3% placebo-adjusted weight loss at 36 weeks; ACCESS II 44-week topline data are expected in Q1 2026, with Phase 3 initiation expected in 2H 2026. Initial Phase 1 data for ACCG-2671 and Phase 1 initiation of ACCG-3535 are expected in 2H 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$109M$170M+ $714M short-term inv.$31M-$117M operating cash flowreport ↗
2023-FY—$70M$130M+ $338M short-term inv.$22M-$79M operating cash flowreport ↗
2022-FY—$36M$26M+ $65M short-term inv.$13M-$46M operating cash flowreport ↗
2021-FY——$105M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-21Coll Crespo Blas · CHIEF MEDICAL OFFICERConversion12,024——Form 4
2026-09-21Coll Crespo Blas · CHIEF MEDICAL OFFICERConversion (derivative)4,008——Form 4
2026-09-21Coll Crespo Blas · CHIEF MEDICAL OFFICEROpen-market sale (derivative)4,008$36.15$145KForm 4
2026-09-18Coll Crespo Blas · CHIEF MEDICAL OFFICERTax withholding10,626$11.67$124KForm 4
2026-09-01Lin Xichen · CHIEF SCIENTIFIC OFFICEROption exercise17,817$0.34$6KForm 4
2026-09-01Lin Xichen · CHIEF SCIENTIFIC OFFICERConversion17,817——Form 4
2026-09-01Lin Xichen · CHIEF SCIENTIFIC OFFICEROption exercise (derivative)17,817——Form 4
2026-09-01Lin Xichen · CHIEF SCIENTIFIC OFFICERConversion (derivative)5,939——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 193 reporting institutions held 66.9M shares ($3.1B, 31.4% of shares outstanding).

#InstitutionSharesValue
1FMR LLC8,403,449$405.0M
2WELLINGTON MANAGEMENT GROUP LLP7,260,287$349.9M
3Avoro Capital Advisors LLC6,555,555$316.0M
4JANUS HENDERSON GROUP PLC5,354,981$258.3M
5Deep Track Capital, LP4,279,848$206.3M
6BVF INC/IL3,459,358$166.7M
7MORGAN STANLEY2,305,457$111.1M
8PRINCIPAL FINANCIAL GROUP INC1,753,764$84.5M
9Driehaus Capital Management LLC1,577,356$76.0M
10ORBIMED ADVISORS LLC1,475,403$71.1M
11AMERICAN CENTURY COMPANIES INC1,438,031$69.3M
12BAKER BROS. ADVISORS LP1,432,529$69.0M
13Siren, L.L.C.1,328,698$64.0M
14Casdin Capital, LLC1,175,000$56.6M
15CAPITOLIS LIQUID GLOBAL MARKETS LLC1,151,300$55.5M